A pathway approach including genes linked to osteosarcoma treatment was used by most of the included studies, so consequently members of the ABC transporter family were included in the pharmacogenetic investigations and sometimes found to be associated to the outcomes of interest. This evidence concerns the gene ABCG2 and osteosarcoma.